An observational study in Heart Failure, Myocarditis and Sepsis, sponsored by NHS Greater Glasgow and Clyde. Status unknown at 2 sites in United Kingdom. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-03-08.
Sponsored by NHS Greater Glasgow and Clyde · Observational
Cardiac dysfunction is common following hospital admission with sepsis and one of the most frequent causes for readmissions to hospital, however underlying mechanisms by which this might occur are unclear. The CONDUCT-ICU investigators will conduct a pilot, cohort study, characterizing cardiac function in ICU survivors of sepsis using a combination of CMR imaging, biomarkers and patient reported outcome measures to investigate mechanisms of cardiac dysfunction following sepsis. Comparisons will be made to that of the general population.
Sepsis is one of the most common reasons for admission to ICU in the UK and it is well established that adverse cardiovascular events are common following sepsis. In fact, the risk of adverse cardiovascular events such as MI, Heart Failure and Stroke is in excess of 60% greater compared to those who have not had sepsis. Similarly, heart failure is one of the most common causes of readmission to hospital following an episode of sepsis. The underlying mechanisms for this phenomenon are unclear and CONDUCT-ICU investigators intend on answering this question.
Investigators will collect cardiac and inflammatory biomarkers from participants at the point of discharge from ICU. Following discharge from hospital, cardiac magnetic resonance (CMR) scans of the heart will be undertaken in participants 6-10 weeks post-discharge from hospital to examine for evidence of inflammation in the heart. Further blood samples will also be collected to look for evidence of inflammation and heart muscle injury at this point in addition to patient reported outcomes measures using validated questionnaires.
Participants will be identified with their direct clinical team in ICU and are nearing or at the point of discharge from ICU. If eligible for the study, they will be approached by researchers and provided them with an information sheet and written consent form. Participants will be given up to 24hrs to decide if they wish to take part in research and if so, they will sign the consent form. Participants are free to withdraw from the study at any time, without any reason given, and this would not affect the standard of care they receive.
This is an observational cohort study. If willing to take part, participants will receive the normal follow-up that would be undertaken following discharge from ICU. In addition, researchers will collect a sample of blood from participants at the time of discharge from ICU and again at 6 -10 weeks post discharge. A Cardiac Magnetic Resonance (CMR) scan will be undertaken 6-10 weeks follow up.
Researchers will assess the patient's day-to-day function and quality of life by asking them to complete validated questionnaires. These questionnaires should take five to ten minutes to complete and help will be available if required. Participants will complete these questionnaires at the follow-up visit 6-10 weeks following discharge from hospital with the help of the researchers conducting the study
The first blood sample will be collected following discharge from ICU whilst the patient is still in hospital. Further blood samples will be collected 6-10 weeks following discharge from hospital. Blood samples for patients undergoing CMR will be taken when they attend for scan. Blood sampling for patients who do not undergo CMR imaging will attend for a separate follow-up visit for collection of samples.
Patients are normally invited to attend ICU follow-up via the InS:PIRE service at approximately 6-10 weeks post-discharge. Where possible researchers will combine blood sample analysis with routine follow-up visits in clinic to which participants would normally be invited. If they are not able to attend follow-up and are not attending for CMR scan, then researchers will invite them to the research facility within the local sites for collection of samples.
Samples will be stored in NHS Biorepository and analyzed within the British Heart Foundation Laboratory at the University of Glasgow.
1,899 studies on the registry are indexed under Sepsis; 462 are open to participants now.
This study's planned enrollment of 69 is below the median of 160 across 931 observational studies indexed under Sepsis.
Browse Sepsis studies →NHS Greater Glasgow and Clyde is the lead sponsor of 215 studies on the registry; 39 are open to participants now.
Counted across the registry records on this site, refreshed daily.
ICU Survivors of Sepsis
Exclusion Criteria:
Contraindications to magnetic resonance imaging:
i. Cardiac pacemaker, artificial heart valve, neurostimulator, cochlear implant ii. Aneurysm clips iii. Metal injuries to the eye iv. Loose metal in any part of the body v. Severe claustrophobia
ICU survivors of sepsis who would routinely attend ICU follow-up.
Diagnostic Test: CMR · Diagnostic Test: hs-troponin · Diagnostic Test: NT-pro BNP · Diagnostic Test: CRP · Diagnostic Test: IL1-B · Diagnostic Test: IL-6 · Diagnostic Test: IL-10 · Diagnostic Test: TNF-alpha
CMR Imaging 6-10 weeks post hospital discharge.
Biomarker of myocardial injury
Biomarker for heart failure
Acute phase inflammatory marker
Inflammatory biomarker
Inflammatory Biomarker
Inflammatory Biomarker
Inflammatory Biomarker
Left Ventricular Ejection Fraction
LVEF is a validated marker of cardiovascular function. It can be used in diagnosis of heart failure and can assist in grading severity.
Time frame: 6-10 weeks post hospital discharge
hs-Troponin (ng/L)
Marker of myocardial injury commonly used in clinical practice
Time frame: 6-10 weeks post-hospital discharge
NT-proBNP (pg/ML)
Biomarker of myocardial dysfunction used in patients with heart failure and associated conditions.
Time frame: 6-10 weeks post-hospital discharge
CRP (mg/L)
Acute phase biomarker of inflammation.
Time frame: 6-10 weeks post discharge
IL-10 (pg/ml)
Inflammatory cytokine thought to inhibit innate immune response.
Time frame: 6-10 weeks post discharge
IL-1B (pg/ml)
Acute phase inflammatory cytokine and pyrogen.
Time frame: 6-10 weeks post discharge
TNF-alpha (pg/ml)
Inflammatory cytokine implicated in acute inflammation and targeted for management of inflammatory and autoimmune disease
Time frame: 6-10 weeks post discharge
IL-6 (pg/ml)
Inflammatory biomarker associated with adverse cardiovascular outcomes and adverse mortality in critically ill patients
Time frame: 6-10 weeks post discharge
Brief Pain Inventory Score
Validated Assessment of Pain. Scores of 0 indicate no pain and scores of 10 indicate the 'worst pain you can imagine'.
Time frame: 6-10 weeks post discharge
ID Pain Score
Validated assessment tool for differentiation of neuropathic pain. Patients describe character of pain using 'yes' or 'no' questions.
Time frame: 6-10 weeks post discharge
EuroQol 5-Dimension (5D) Score
Validated measure of quality of life. Part of core outcome measures in critical illness survivors. Scores 5 domains (Mobility, Self-Care, Usual Activities, Pain/Discomfort, Anxiety /Depression) on likert scale as follows: 1) No problems, 2) Slight Problems, 3) Moderate Problems, 4) Severe Problems, 5) Unable
Time frame: 6-10 weeks post discharge
Hospital Anxiety and Depression Score
Validated measure of anxiety and depression. Previously used in survivors of critical illness. Total score: 0-7 = Normal, 8-10 Borderline abnormal (borderline case), 11-21 Abnormal (case)
Time frame: 6-10 weeks post discharge
Dukes Activity Status Index
Validated tool for assessing functional capacity. Scores 0 - 58.2, with higher scores indicating better functional capacity.
Time frame: 6-10 weeks post discharge
Vitality Domain of Short Form 36 - Score
Validated tool for vitality and used in survivors of critical illness. Likert Scale Assessing vitality. Answers range from 1)All of the time, most of the time, a good bit of the time, some of the time, a little bit of the time, none of the time.
Time frame: 6-10 weeks post discharge
MRC Breathlessness Scale
Widely used grading system for breathlessness in survivors of critical illness. Graded 0-4.4 indicates more severe breathlessness.
Time frame: 6-10 weeks post discharge
Myocardial Native T1 and T2 Mapping
CMR markers of subtle inflammation and fibrosis commonly examined during CMR imaging.
Time frame: 6-10 weeks post discharge
Successful follow-up rate of participants invited to attend CMR scans. i.e. Feasibility of CMR imaging
To evaluate feasibility of undertaking CMR in complex post-ICU cohort of patients. To the investigators' best knowledge, this cohort has never been investigated before in this way and it is unclear to what extent participants will be able to attend follow up. We will evaluate the attendance rate at CMR follow-up measured against participants invited to take part in the study.
Time frame: 6-10 weeks post discharge
Plan to share: No
No publications or documents are linked to this record.
This study is status unknown, as verified in Mar 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
NHS Greater Glasgow and Clyde